| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the University of Rochester School of Medicine and Dentistry (Drs. Jung and Dworkin), Rochester, NY; the University of Bristol and Bristol Royal Infirmary (Dr. Johnson), Bristol, UK; and GlaxoSmithKline (D.R.J. Griffin), Harlow, Essex, UK.
Address correspondence and reprint requests to Dr. Robert H. Dworkin, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 604, Rochester, NY 14642; e-mail: robert_dworkin{at}urmc.rochester.edu
Objectives: To identify risk factors for postherpetic neuralgia (PHN) using a validated definition of this chronic neuropathic pain syndrome, to determine combinations of risk factors that identify patients with a high risk of developing PHN, and to examine the characteristics of patients with subacute herpetic neuralgia, that is, pain that persists beyond the acute phase of herpes zoster but that resolves before PHN can be diagnosed.
Methods: The authors examined baseline and follow-up data from 965 herpes zoster patients enrolled within 72 hours of rash onset in two clinical trials of famciclovir.
Results: Univariate and multivariate analyses indicated that older age, female sex, presence of a prodrome, greater rash severity, and greater acute pain severity made independent contributions to identifying which patients developed PHN. Patients with subacute herpetic neuralgia who did not develop PHN were significantly younger and had less severe acute pain than PHN patients but were significantly more likely to have severe and widespread rash than patients without persisting pain.
Conclusions: The independent contributions to the prediction of PHN made by older age, female sex, presence of a prodrome, greater rash severity, and greater acute pain severity suggest that these risk factors reflect different mechanisms that each contribute to the development of PHN. Subacute herpetic neuralgia that does not progress to PHN may reflect peripheral tissue damage and inflammation caused by a particularly severe or widespread rash.
Received July 21, 2003. Accepted in final form December 29, 2003.
This article has been cited by other articles:
|
|
 |
|
  R. J. Whitley A 70-Year-Old Woman With Shingles: Review of Herpes Zoster JAMA, July 1, 2009; 302(1): 73 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Fuks, D. Shitrit, B. D. Fox, A. Amital, Y. Raviv, I. Bakal, and M. R. Kramer Herpes zoster after lung transplantation: incidence, timing, and outcome. Ann. Thorac. Surg., February 1, 2009; 87(2): 423 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Hicks, R. H. Cook-Norris, N. Mendoza, V. Madkan, A. Arora, and S. K. Tyring Family History as a Risk Factor for Herpes Zoster: A Case-Control Study Arch Dermatol, May 1, 2008; 144(5): 603 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. I. Gilderman, J. F. Lawless, T. M. Nolen, T. Sterling, R. Z. Rutledge, D. A. Fernsler, N. Azrolan, S. C. Sutradhar, W. W. Wang, I. S. F. Chan, et al. A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of Zostavax Clin. Vaccine Immunol., February 1, 2008; 15(2): 314 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W Wareham and J. Breuer Herpes zoster BMJ, June 9, 2007; 334(7605): 1211 - 1215. [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Weaver The Burden of Herpes Zoster and Postherpetic Neuralgia in the United States J Am Osteopath Assoc, March 1, 2007; 107(suppl_1): S2 - S7. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. van Seventer, A. Sadosky, M. Lucero, and E. Dukes A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia Age Ageing, March 1, 2006; 35(2): 132 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Andrei, J. van den Oord, P. Fiten, G. Opdenakker, C. De Wolf-Peeters, E. De Clercq, and R. Snoeck Organotypic Epithelial Raft Cultures as a Model for Evaluating Compounds against Alphaherpesviruses Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4671 - 4680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Opstelten, G. A van Essen, K. G. Moons, A. J. van Wijck, F. G Schellevis, C. J Kalkman, and T. J. Verheij Do herpes zoster patients receive antivirals? A Dutch national survey in general practice Fam. Pract., October 1, 2005; 22(5): 523 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Tenser and R. H. Dworkin Herpes zoster and the prevention of postherpetic neuralgia: Beyond antiviral therapy Neurology, August 9, 2005; 65(3): 349 - 350. [Full Text] [PDF]
|
|
|
|
|
|
R. R. Edwards Individual differences in endogenous pain modulation as a risk factor for chronic pain Neurology, August 9, 2005; 65(3): 437 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Opstelten and M. J W Zaal Managing ophthalmic herpes zoster in primary care BMJ, July 16, 2005; 331(7509): 147 - 151. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
